Showing 139–144 of 229 results
English Name: Lemborexant
Alias: (1R,2S)-2-[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide; E 2006
Product Name: Lemborexant; Lemborexant
Molecular Structure: CAS Registry Number: 1369764-02-2, Lemborexant
Molecular Formula: C22H20F2N4O2
Molecular Weight: 410.42
CAS Registry Number: 1369764-02-2
Product Name: Lenvatinib
CAS Number: 417716-92-8
Purity: 99.0%
Product Category: API
Synonyms:
E7080
Lenvatinib (E7080)
4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide
ER-203492-00
Molecular Formula: C21H19ClN4O4
Molecular Weight: 426.85
Keywords:
Lenvatinib; 417716-92-8; E7080; Lenvatinib mesylate; 857890-39-2
Product Name: Lenvatinib Mesylate
CAS No.: 857890-39-2
Purity: 99.0%
Category: API
Synonyms:
Lenvatinib mesylate
E7080 mesylate
4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide monomethanesulfonate
Molecular Formula: C₂₁H₁₉ClN₄O₄·CH₄O₃S
Molecular Weight: 522.96
Product Description:
Lenvatinib Mesylate is an oral molecular targeted anti-cancer agent. It was approved by the U.S. FDA on February 13, 2015, for the treatment of progressive, locally advanced or metastatic differentiated thyroid cancer (DTC) refractory to radioactive iodine (RAI). It was granted accelerated assessment by the European Medicines Agency, receiving approval just 9 months after submission.
This decision was based on the SELECT Phase III multicenter, randomized, double-blind, placebo-controlled trial. Lenvatinib significantly improved progression-free survival (PFS) compared to placebo.
The study highlighted Lenvatinib’s rapid response, with a median time to first objective response of 2 months. It also demonstrated a statistically significant increase in objective response rate (ORR), including complete responses in 1.5% of patients.
Mechanistically, Lenvatinib selectively inhibits several receptor tyrosine kinases involved in tumor angiogenesis and growth, including VEGFR, FGFR, RET, KIT, and PDGFR. Structural studies reveal that it binds to VEGFR2 in a unique Type II binding mode, enabling potent and rapid inhibition of kinase activity.
Keywords:
857890-39-2; 417716-92-8; Lenvatinib; Lenvatinib Mesylate; E7080
Letermovir is a novel antiviral drug developed by Merck & Co. for the treatment of cytomegalovirus (CMV) infection in CMV-seropositive adult patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). It was approved by the U.S. FDA on November 9, 2017, and is marketed under the brand name Prevymis.
Letermovir (also known as AIC246 or MK-8228) is a novel anti-CMV compound that targets the viral terminase complex. It remains active against CMV strains resistant to DNA polymerase inhibitors.
AIC246 inhibits viral replication without blocking the synthesis of progeny CMV DNA or viral proteins. It is currently one of the most potent agents against human cytomegalovirus (HCMV), with an EC₅₀ of approximately 5 nM in cell-based assays and a selectivity index greater than 15,000.
In mouse xenograft models, mice treated with AIC246 showed dose-dependent reductions in HCMV titers within transplanted cells compared to placebo-treated controls.
Chinese Name: 利拉利汀
English Name: Linagliptin
CAS Number: 668270-12-0
Validity: One year
Storage Conditions: Store at room temperature, protected from light
Purity: 99.0%
Product Category: Active Pharmaceutical Ingredient (API)
Linagliptin, developed by Boehringer Ingelheim, was approved by the FDA on May 2, 2011. It is used in combination with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin works by inhibiting dipeptidyl peptidase-4 (DPP-4), thereby improving glycemic control in patients.
Compared with other DPP-4 inhibitors, Linagliptin offers the following main advantages:
Excellent renal safety profile
Effectively reduces glycated hemoglobin (HbA1c) levels
Primarily excreted unchanged in feces; only about 5% of the oral dose is excreted via the kidneys
Even with intravenous administration, only 30.8% is renally excreted
No need for regular liver or kidney function monitoring or dose adjustment
Fixed dosing for all patients, making prescription more convenient
668270-12-0; Linagliptin; DPP-4 inhibitor; Type 2 diabetes treatment; high purity API; Boehringer Ingelheim; antidiabetic drug; no dose adjustment; renal safety; fixed dose therapy
English Name: Lotilaner
Alias: 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]thiophene-2-carboxamide
Product Name: Lotilaner
Molecular Formula: C20H14Cl3F6N3O3S
Molecular Weight: 596.76
CAS Registry Number: 1369852-71-0
EC Number: 852-014-9
关键字： 1369852-71-0;洛替拉纳;Lotilaner;